Consideration for Use of Novel Agents in Acute Myeloid Leukemia

There is a need for improved therapeutic strategies to combat AML disease progression.  Recent developments have expanded treatment options for acute myeloid leukemia (AML) including targeted agents, antibody-drug conjugates and novel formulations. Based on molecular markers, some novel targeted treatment options are associated with improved clinical outcomes and fewer side effects than the conventional standard regimens.  These advances have been facilitated in part by the discovery of genetic mutations that play integral roles in AML development and progression. As more novel agents enter the treatment landscape, it is important for clinicians to be aware of how to incorporate these treatment options into clinical practice in ways that achieve meaningful patient outcomes.  Informing clinicians about these therapeutic advances will aid in their incorporation into standard regimens for the appropriate subpopulations of patients with AML.

This information was originally presented at the NCCN 13th Annual Congress: Hematologic Malignancies™ held in New York, New York, from September 21-22, 2018.

Target Audience

This educational program is designed to meet the educational needs of oncologists, hematologists, nurses, pharmacists, and other health care professionals who manage patients with hematologic malignancies.

Learning Objectives

Following this activity, participants should be able to:

  • Summarize novel treatment options used in the management of acute myeloid leukemia (AML). 
  • Outline molecular markers or genes with prognostic significance in AML and associated targeted agents.
  • Identify emerging targeted agents in the management of AML.
Additional information
Supporters: 

This activity is supported by educational grants from:

  • Astellas
  • AstraZeneca
  • Celgene Corporation
  • Genentech
  • Jazz Pharmaceuticals, Inc.
  • MEI Pharma
  • Novartis
  • Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
  • Pfizer
  • Sanofi Genzyme
  • Takeda Oncology

This activity is supported by independent educational grants from AbbVie and Incyte.

This activity is supported by educational funding provided by Amgen.

This activity is supported by an unrestricted educational grant from Gilead Sciences, Medical Affairs.

Course summary
Available credit: 
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.55 ANCC contact hours
  • 0.50 Participation
Course opens: 
11/01/2018
Course expires: 
11/01/2019
Cost:
$0.00

Richard M. Stone, MD
Dana-Farber Cancer Institute

Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education (CE) activities are expected to disclose any relevant financial relationships with a commercial interest as defined by ACCME’s, ACPE’s, and ANCC’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

Definitions

NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.

NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

Faculty Disclosures

The faculty listed below discloses the following relevant financial relationships:

Richard M. Stone, MD
AbbVie, Inc.: Consulting Fee
Actinium Pharmaceuticals, Inc.: Scientific Advisor
Agios, Inc.: Consulting Fee; Grant/Research Support
Amgen Inc.: Consulting Fee
Argenx: Other financial benefit
Arog Pharmaceuticals, Inc.: Consulting Fee; Grant/Research Support
Astellas Pharma US, Inc.: Consulting Fee
Celgene Corporation: Consulting Fee; Other financial benefit; Scientific Advisor
Fujifilm Corporation: Consulting Fee
Jazz Pharmaceuticals Inc.: Consulting Fee
Novartis Pharmaceuticals Corporation: Consulting Fees, Honoraria; Grant/Research Support
Orsenix Holdings BV: Consulting Fee
Otsuka America Pharmaceutical, Inc.: Consulting Fee
Pfizer Inc.: Consulting Fee
Rafael Pharmaceuticals, Inc. (formerly Cornerstone
Pharmaceuticals, Inc.): Consulting Fee
Sumitomo Dainippon Pharma Co., Ltd.: Consulting Fee

NCCN Staff Disclosures

The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Robert W. Carlson, MD; Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa G. Kimbro, MBA, CPA (employed by NCCN until 8/10/2018); Joan S. McClure, MS (employed by NCCN until 8/1/2018); Lisa Perfidio, MS; Shannon Ryan; Kathy Ann Smith, CMP, CHCP; Gary J. Weyhmuller, MBA, SPHR

The NCCN Activity Planning staff listed below discloses the following relevant financial relationships:

Donald Harting, ELS, CHCP
Laboratory Corporation of America (LabCorp): Equity interest/Stock Options

Katherine Pierce
Pfizer Inc.: Equity Interest/Stock Options
Boston Scientific Corporation: Equity Interest/Stock Options

The NCCN Clinical staff listed below discloses no relevant financial relationships:

Ndiya Ogba, PhD

Physicians
National Comprehensive Cancer Network is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NCCN designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 0.50 hour of Category 1 credit for completing this activity.

Nurses
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

NCCN designates this educational activity for a maximum of 0.55 contact hour.

Pharmacists

National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

NCCN designates this knowledge-based continuing education activity for 0.50 contact hour (0.05 CEUs) of continuing education credit. UAN: 0836-0000-18-110-H01-P

Available Credit

  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.55 ANCC contact hours
  • 0.50 Participation

Accreditation Period

Course opens: 
11/01/2018
Course expires: 
11/01/2019

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need: